Fig. 1A



2000
1500
1000
500
0
Tumor Volume (mm3)
72 mg/kg
0 3 6 9 12 15 18 21
Time (Days)
Dose

Fig. 1B



2500
2000
1500
1000
500
0
Tumor Volume (mm3)
150 mg/kg
(large tumors)
0 3 6 9 12 15 18 21 24 27
Time (days)

Fig. 2



Dosing Days:
Conjugate 1
PARP inhibitor
Concentration (%)
1000
100
10
1
0
0
1
2
3
4
5
6
7
PARP inhibitor plasma
Conjugate 1 Tumor Xenograft
Conjugate 1 plasma
Time (days)

Fig. 3A



Ovary BRCA WT (SKOV3)
Talazoparib
(0.33 mg/kg days 2-5/week x 6)
Average Tumor Volume (mm3)
1000
800
600
400
200
0
0
10
20
30
40
Time (Days)
Vehicle
Conj. 1 (75 mg/kg day 1/week x 6)
Conj. 1
(75 mg/kg day 1/week x 6)
+ Talazoparib
(0.33 mg/kg days 2-5/week x 6)

Fig. 3B




NSCLC BRCA WT (NCI-H460)
Average Tumor Volume (mm3)
1500
1000
500
0
0
5
10
Time (Days)
Vehicle
Talazoparib
(0.33 mg/kg days 2-5, 9-12)
Conj. 1(100 mg/kg days 1, 8)
Conj. 1
(100 mg/kg days 1, 8)
+ Talazoparib
(0.33 mg/kg days 2-5, 9-12)

Fig. 3C


Sustained And Synergistic DNA Damage 7 Days After Dosing Conjugate 1 + Talazoparib
pH2AX quantity in NCI-H460 NSCLC xenograft tumors
pH2AX (relative to loading control)
0.8
0.6
0.4
0.2
0.0
Talazoparib 0.33 mg/kg
Conj. 1 75 mg/kg
Conj. 1 75 mg/kg + Talazoparib 0.33 mg/kg